Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on Persistence on Certolizumab and Predictors Thereof in with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial-Spondyloarthritis Patients: Biopure Registry (The BIOlogic aPUlian REgistry)

Next Previous
Trial Profile

Study on Persistence on Certolizumab and Predictors Thereof in with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial-Spondyloarthritis Patients: Biopure Registry (The BIOlogic aPUlian REgistry)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 02 Apr 2019 Results assessing the the effectiveness of certolizumab and identify any predictors of favorable outcome in patients with RA, PsA, or SpA (n=355) published in the Clinical Drug Investigation
  • 15 Jul 2018 New trial record
  • 16 Jun 2018 Results (n=345) assessing Drug Survival on Certolizumab, presented at the 19th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top